Syncromune
Clinical-stage immuno-oncology — in-situ vaccination (SYNC-T) platform
Biotech
Current Valuation
Private
PRIVATE
Syncromune is a private biotech company that filed a SEC Form D on 2026-05-11 disclosing a $144.8M Regulation D offering. Officers and directors of record include Charles Link, Eamonn Hobbs, Joseph Gerardi, Agustin Gago, Joseph Maroon. Additional company details to be enriched from press and IR sources.
Company Profile
Growth
Filed SEC Form D on 2026-05-11 for $144.8M Regulation D offering
Last Round
Form D filing — $145M (May 2026)
Fundraising Status
Form D filing · $145M · 2 mo ago
privateTotal raised $145M
Latest Funding Round
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Form D filing | $145M | May 2026 | — | — |
Investors
Joseph Maroon · Douglas Watson · Jeffrey Cleland · Norman Schwartz
BiotechNew
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.